The effect on kidney function, vasoactive systems and ascites outcome of long-term treatment with propranolol plus isosorbide-5-mononitrate, a combined therapy proven more effective than propranolol alone in decreasing portal pressure in the cirrhotic patient, is unknown. Thirty cirrhotic patients w
Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension
✍ Scribed by Agustín Albillos*; Juan–Carlos García–Pagán‡; Jerónimo Iborra*; Juan–Carlos Bandi‡; Guillermo Cacho*; María Pérez–Paramo§; Angels Escorsell‡; José Luis Calleja*; Pedro Escartín*; Jaime Bosch‡
- Book ID
- 118520325
- Publisher
- Elsevier Science
- Year
- 1998
- Tongue
- English
- Weight
- 155 KB
- Volume
- 115
- Category
- Article
- ISSN
- 0016-5085
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
The long-term hemodynamic and renal effects of propranolol were compared with those of propranolol plus isosorbide dinitrate in 44 portal-hypertensive alcoholic cirrhotic patients. Eight control patients, 8 patients receiving propranolol and 14 patients receiving propranolol plus isosorbide dinitrat
This study investigated whether oral doses of isosorbide-5-mononitrate, a preferential venous dilator that decreases portal pressure, could enhance the effects of propranolol on portal hypertension. Taking part in the study were 28 patients with cirrhosis and portal hypertension. Twenty patients (gr